HBW Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say

Executive Summary

FDA should accept “a reasonable likelihood of patient benefit” as the appropriate standard for approving therapies for unmet medical needs, the National Venture Capital Association and its Medical Innovation & Competitiveness Coalition contend.

Related Content

Congress Dives Into Biomedical Innovation: Will It Drown In A Deep Sea Of Competing Needs?
How "Clean" Will PDFUA V Be? Rep. Pitts Explains His Vacuuming Technique
Tax Incentives To Spur Innovation: BIO's "Big Ideas" Beyond FDA
Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011
Amylin's Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle
BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA
FDA Thinking "Seriously, Deeply" About Range Of Approval Strategies – Hamburg
BIO Seeks Weight-Of-Evidence Standard For Drug Approvals
Pleasant Surprise For InterMune With Early Positive Opinion On Pirfenidone From CHMP
Despite Positive Advisory Committee Vote, InterMune Gets Complete Response For Pirfenidone





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts